Floatz logo

Medroxyprogesterone acetate

Systemic Sclerosis (SSc)

National Institute of Allergy and Infectious Diseases (NIAID)Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Systemic Sclerosis (SSc) cohort.

View all 13

Same molecule, other indications

Medroxyprogesterone acetate is also rated in:

osteoporosisDormant
BBB
Indicative ·
72 / 100
View asset →
cardiovascular disorderDormant
BB
Indicative ·
65 / 100
View asset →
sickle cell diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →